Jeremy A. Cubert is a Partner in the firm’s Intellectual Property Practice. With over 22 years of experience in patent law with an emphasis in life sciences, Mr. Cubert assists companies in all aspects of obtaining and managing their intellectual property portfolios. He has extensive experience in patent prosecution, due diligence and analysis of intellectual property portfolios and counsels clients regarding the acquisition and licensing of intellectual property assets. Mr. Cubert regularly works directly with scientists and professionals at academic institutions, biotechnology companies, and Fortune 500 companies to develop intellectual property development and management plans.
Mr. Cubert has been an Adjunct Professor at the American University Washington College of Law where he taught a course entitled “Intellectual Property Law and Healthcare” and has authored many articles in the area of intellectual property law.
Representative Experience
- Conducted intellectual property due diligence studies for venture capital firms establishing six biopharmaceutical companies
- Drafted and prosecuted hundreds of patent applications in the biological sciences, pharmaceutical, and food science industries
- Negotiated hundreds of technology transactions with large and small companies, universities, and government agencies
- Developed intellectual property management programs for large and small organizations
Honors & Awards
- National Law Journal Intellectual Property Trailblazer, 2017
- Legal 500 Life Sciences, 2011
Publications and Speeches
- Co-Author of Book Chapter for forthcoming book “Research Handbook on the Law of Artificial Intelligence,” Edward Elgar Press, 2018
- Presenter at ACI’s IP Due Diligence Conference, Philadelphia, PA, November 2-3, 2017.
- “After The Term Sheet,” Webinar with Jeremy Cubert and David Thibodeau, November 17, 2017
- “Crossing the Chasm: Avoiding and Surviving the PTAB,” IP Watchdog, September 14, 2017, Jeremy Cubert and David Thibodeau
- “Securing Ownership Rights in Patents In The Real World,” IP Watchdog, September 8, 2017
- “How To Create Patent Rights,” IP Watchdog, August 7, 2017
- Quoted in the Law360article “PTAB, Courts’ Differing Patent Takes Raise Fairness Questions.” April 11, 2017
- Quoted in the IP Law360 Article, “Hedge Fund Drug Patent Challenges In Doubt After Bass’ Test,” April 1, 2017
- “Is The Peer Review Crisis a Patent Application Crisis?,” JD Supra, April 11, 2017
- “Publish or Perish? The Balance Between Public Disclosure and IP Protection in Scientific Research,” JD Supra, March 20, 2017
- “How Addressing The ‘Triumvirate of Patent Risks’ Can Enhance Your IP Portfolio Value,” JD Supra, February 14, 2017
- “Top 5 Patent Red Flags In Life Science Due Diligence,” JD Supra, January 12, 2017
- “Who Owns IP Rights in The Age of Artificial Intelligence?,” JD Supra, January 4, 2017
Education
George Mason University School of Law, JD, 1995
University of Medicine and Dentistry of New Jersey, MS in Biochemistry and Molecular Biology, 1989
Rutgers University, BS in Biology, 1987
Previous Experience
- Clinical Technology Transfer Group, PLLC, Member
- Dickstein Shapiro, Partner
Areas of Practice
Admissions
- District of Columbia
- Maryland
- U.S. Patent and Trademark Office